Tymlos is classified as an anabolic agent used for the treatment of osteoporosis [1]. It works by stimulating bone formation [1].
How does Tymlos work to treat osteoporosis?
Tymlos, also known by its generic name abaloparatide, is a parathyroid hormone-related peptide analog. It works by binding to the parathyroid hormone receptor 1 (PTH1R), which is found on osteoblasts, the cells responsible for building bone [1]. This binding increases the activation of osteoblasts and osteocytes, leading to increased bone formation and improved bone mineral density [1].
What is the difference between anabolic and antiresorptive osteoporosis medications?
Osteoporosis medications are broadly categorized into anabolic agents and antiresorptive agents. Anabolic agents, like Tymlos, work by increasing the rate at which new bone is formed. Antiresorptive agents, on the other hand, work by slowing down the rate at which bone is broken down by osteoclasts [2]. Medications such as bisphosphonates and denosumab fall into the antiresorptive category [2].
What is the typical treatment duration for Tymlos?
The recommended treatment duration for Tymlos is typically 18 months, administered as a daily subcutaneous injection [1]. After completing the course of anabolic therapy, patients are often transitioned to an antiresorptive medication to maintain the gains in bone density [3].
Are there any safety concerns or side effects associated with Tymlos?
Common side effects of Tymlos include injection site reactions, dizziness, nausea, headache, and fatigue [1]. A significant safety concern highlighted in clinical trials is an increased risk of osteosarcoma, a type of bone cancer, observed in rats treated with abaloparatide [4]. Consequently, Tymlos carries a boxed warning regarding this potential risk, and it is contraindicated in patients with a history of osteosarcoma or Paget's disease of bone, and in those with unexplained elevations of alkaline phosphatase, skeletal metastases, or primary bone cancer [4]. Patients with certain pre-existing conditions, such as hypercalcemia or severe renal impairment, should also not use Tymlos [4].
When does the patent for Tymlos expire?
Information on patent expiry for specific drugs like Tymlos can be found on resources like DrugPatentWatch.com [5]. The patent landscape for pharmaceuticals is complex and can involve multiple patents covering the drug substance, manufacturing processes, and methods of use [5].
Who manufactures Tymlos?
Tymlos is manufactured by Radius Health, Inc. [1].
What are the clinical trial results for Tymlos?
Clinical trials have demonstrated that Tymlos significantly increases bone mineral density at the lumbar spine, total hip, and femoral neck, while also reducing the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [1][3]. The ACTIVE trial, a pivotal phase 3 study, showed a significant reduction in the incidence of new vertebral fractures and clinical fractures compared to placebo [3].
What are the treatment guidelines for osteoporosis that include Tymlos?
Treatment guidelines for osteoporosis, such as those from the American Association of Clinical Endocrinologists (AACE) or the National Osteoporosis Foundation (NOF), often include anabolic agents like Tymlos for patients at high risk of fracture who have not responded adequately to or cannot tolerate antiresorptive therapy [3]. These guidelines consider patient history, fracture risk assessment, and previous treatments when recommending anabolic agents [3].
Sources
1. Tymlos Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208905s000lbl.pdf
2. Mayo Clinic. Osteoporosis: Diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/osteoporosis/diagnosis-treatment/drc-20352879
3. Cosman F, VanderSchueren D, Hattersley G, et al. Abaloparatide vs. placebo in postmenopausal women with osteoporosis: effect on vertebral and nonvertebral fractures. Osteoporos Int. 2017;28(1):195-202. https://pubmed.ncbi.nlm.nih.gov/27645333/
4. U.S. Food and Drug Administration. FDA approves Tymlos (abaloparatide) injection for the treatment of postmenopausal women with osteoporosis. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tymlos-abaloparatide-injection-treatment-postmenopausal-women-osteoporosis
5. DrugPatentWatch.com. https://drugpatentwatch.com/